GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » YoY EBITDA Growth

Clarity Pharmaceuticals (Clarity Pharmaceuticals) YoY EBITDA Growth : -33.33% (As of Dec. 2023)


View and export this data going back to 2022. Start your Free Trial

What is Clarity Pharmaceuticals YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. Clarity Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 was -33.33%.

Clarity Pharmaceuticals's EBITDA per Share for the six months ended in Dec. 2023 was $-0.06.

Clarity Pharmaceuticals YoY EBITDA Growth Historical Data

The historical data trend for Clarity Pharmaceuticals's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clarity Pharmaceuticals YoY EBITDA Growth Chart

Clarity Pharmaceuticals Annual Data
Trend Jun22 Jun23
YoY EBITDA Growth
- -8.14

Clarity Pharmaceuticals Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23
YoY EBITDA Growth Get a 7-Day Free Trial - - 8.16 -26.32 -33.33

Clarity Pharmaceuticals YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

Clarity Pharmaceuticals's YoY EBITDA Growth for the fiscal year that ended in Jun. 2023 is calculated as:

YoY EBITDA Growth (A: Jun. 2023 )
=(EBITDA per Share (A: Jun. 2023 )-EBITDA per Share (A: Jun. 2022 ))/ | EBITDA per Share (A: Jun. 2022 ) |
=(-0.093--0.086)/ | -0.086 |
=-8.14 %

Clarity Pharmaceuticals's YoY EBITDA Growth for the quarter that ended in Dec. 2023 is calculated as:

YoY EBITDA Growth (Q: Dec. 2023 )
=(EBITDA per Share (Q: Dec. 2023 )-EBITDA per Share (Q: Dec. 2022 )) / | EBITDA per Share (Q: Dec. 2022 )) |
=(-0.06--0.045)/ | -0.045 |
=-33.33 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clarity Pharmaceuticals YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of Clarity Pharmaceuticals's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Clarity Pharmaceuticals (Clarity Pharmaceuticals) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clarity Pharmaceuticals Ltd (OTCPK:CLRPF) » Definitions » YoY EBITDA Growth
Comparable Companies
ASX:IMU ASX:MSB ASX:OPT ASX:PYC ASX:BOT ASX:IMM ASX:RAC ASX:PAR ASX:PIQ ASX:RCE OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA XBRU:ARGX HKSE:02269 BNTX
Traded in Other Exchanges
CU6:Australia
Address
4 Cornwallis Street, National Innovation Centre, Eveleigh, Sydney, NSW, AUS, 2015
Website
https://www.claritypharmaceuticals.com
Clarity Pharmaceuticals Ltd is a clinical-stage radiopharmaceutical company developing next-generation theranostic (therapy and imaging) products, based on its platform SAR Technology. The SAR technology is ideally suited for use with copper isotopes, enabling superior imaging and therapeutic characteristics of radiopharmaceutical products and addressing the current manufacturing and logistical limitations in the growth of the radiopharmaceutical sector in oncology.